Among patients with acute myeloid leukemia (AML), treatment regimens and outcomes may differ among younger and older adults. Although there is no clear dividing line when considering age in AML, in most studies, "older adults" has been defined as over age 60.
The management of older patients with AML is a difficult challenge . Older adults are more likely to have comorbidities that can limit treatment options; the disease also tends to be more resistant to chemotherapy with more frequent unfavorable AML subtypes; thus, outcomes are worse than in younger patients. (See "Pretreatment evaluation and prognosis of acute myeloid leukemia in older adults".)
This topic review will discuss the treatment of older adults with AML. The following topics are presented separately:
●The treatment of adults of any age with acute promyelocytic leukemia (FAB M3 AML) (see "Initial treatment of acute promyelocytic leukemia in adults")
●The treatment of adults of any age with therapy-related AML (see "Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome")